This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Mirvaso

Galderma S.A.

Drug Names(s): CD07805/47, COL-118, brimonidine, Sansrosa

Description: COL-118 is a topical formulation of Brimonidine, a selective alpha-2 adrenergic receptor agonist.

Deal Structure: CollaGenex and Galderma
In February 2008, CollaGenex Pharmaceuticals announced that it entered into a definitive merger agreement with an affiliate of Galderma Pharma S.A. Upon completion of the merger, CollaGenex will become a wholly-owned subsidiary of Galderma.

In April 2008, CollaGenex became a wholly-owned subsidiary of Galderma.

Maruho and Galderma
In January 2016, Maruho and Galderma Pharma announced that they have agreed to enter into a comprehensive set of agreements to form a strategic alliance focused on the development and commercialization of prescription drugs for dermatology in Japan, including therapies in the fields of acne and rosacea.

Under the terms of the agreements, from July 17, 2016, Maruho will market Differin Gel 0.1%, Galdermas acne vulgaris treatment agent. Maruho will also market the acne vulgaris treatment marketed overseas as Epiduo, currently filed for approval in Japan. Additionally, Maruho will be...See full deal structure in Biomedtracker

Partners: Maruho Co., Ltd.


Mirvaso News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug